Matinas BioPharma Holdings (MTNB) EBIT Margin (2015 - 2023)
Matinas BioPharma Holdings (MTNB) reported EBIT Margin of 854.23% for Q2 2023, down 29685.0% year-over-year from N/an in Q2 2022, and up 42.65% quarter-over-quarter from 1489.6% in Q1 2023.
Matinas BioPharma Holdings (MTNB) EBIT Margin (2015 - 2023) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 8 years of EBIT Margin data on file, last reported at 854.23% in Q2 2023.
- EBIT Margin for Q2 2023 came in at 854.23%, down 29685.0% year-over-year; the trailing twelve-month figure through Dec 2023 was 2168.43% (down 139729.0% YoY), and the FY2023 annual result was 2168.43%, down 139710.0% from the prior year.
- EBIT Margin advanced to 854.23% in Q2 2023 per MTNB's latest filing, from 1489.6% in the prior quarter.
- Over five years, EBIT Margin peaked at 2016293.39% in Q4 2021 and troughed at 19059.52% in Q1 2021.
- A 5-year average of 199274.87% and a median of 705.81% in 2023 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2021 and 2022: EBIT Margin soared 200596620 bps in 2021, then plunged 201680892 bps in 2022.
- A 5-year view of EBIT Margin shows it stood at 5033.49% in 2019, then jumped by 305 bps to 10327.19% in 2020, then jumped by 19424 bps to 2016293.39% in 2021, then slumped by 100 bps to 515.52% in 2022, then slumped by 66 bps to 854.23% in 2023.
- Business Quant data shows MTNB's EBIT Margin at 854.23% in Q2 2023, 1489.6% in Q1 2023, and 515.52% in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -854.23% |
| Mar 31, 2023 | -1,489.60% |
| Dec 31, 2022 | -515.52% |
| Sep 30, 2022 | -513.83% |
| Jun 30, 2022 | -557.38% |
| Dec 31, 2021 | 2,016,293.39% |
| Mar 31, 2021 | -19,059.52% |
| Dec 31, 2020 | 10,327.19% |
| Sep 30, 2020 | -5,848.30% |
| Jun 30, 2019 | -5,033.49% |
| Jun 30, 2018 | -3,791.13% |
| Mar 31, 2018 | -13,764.74% |
| Dec 31, 2017 | -10,311.72% |
| Sep 30, 2017 | -7,589.85% |
| Jun 30, 2017 | -8,854.73% |
| Mar 31, 2017 | -29,976.78% |
| Sep 30, 2015 | -3,606.48% |
| Jun 30, 2015 | -3,119.21% |
| Mar 31, 2015 | -4,456.62% |